Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

Jason A Tye-Din; A James M Daveson; Gautam Goel; Kaela E Goldstein; Holly L Hand; Kristin M Neff; Alina Popp; Juha Taavela; Markku Maki; Jorma Isola; Leslie J Williams; Kenneth E Truitt; Robert P Anderson; RESET CeD Study Group

doi:10.1016/S2468-1253(22)00428-9

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

Jason A Tye-Din, A James M Daveson, Gautam Goel, Kaela E Goldstein, Holly L Hand, Kristin M Neff, Alina Popp, Juha Taavela, Markku Maki, Jorma Isola, Leslie J Williams, Kenneth E Truitt, Robert P Anderson, RESET CeD Study Group

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

21 Sitaatiot (Scopus)

76 Lataukset (Pure)

Alkuperäiskieli	Englanti
Sivut	446-457
Sivumäärä	12
Julkaisu	The Lancet gastroenterology & hepatology
Vuosikerta	8
Numero	5
DOI - pysyväislinkit	https://doi.org/10.1016/S2468-1253(22)00428-9
Tila	Julkaistu - 2023
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Julkaisufoorumi-taso

Jufo-taso 2

Pääsy asiakirjaan

10.1016/S2468-1253(22)00428-9

Efficacy and safety of glutenAccepted author manuscript, 715 KBLisenssi: CC BY-NC-ND

https://urn.fi/URN:NBN:fi:tuni-202303303333Lisenssi: CC BY-NC-ND

Siteeraa tätä

Tye-Din, J. A., Daveson, A. J. M., Goel, G., Goldstein, K. E., Hand, H. L., Neff, K. M., Popp, A., Taavela, J., Maki, M., Isola, J., Williams, L. J., Truitt, K. E., Anderson, R. P., & RESET CeD Study Group (2023). Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study. The Lancet gastroenterology & hepatology, 8(5), 446-457. https://doi.org/10.1016/S2468-1253(22)00428-9

Tye-Din, Jason A ; Daveson, A James M ; Goel, Gautam et al. / Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD) : an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study. Julkaisussa: The Lancet gastroenterology & hepatology. 2023 ; Vuosikerta 8, Nro 5. Sivut 446-457.

@article{eb01df7f8d3a4dd38ad0d005f5a2cabf,

title = "Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study",

author = "Tye-Din, {Jason A} and Daveson, {A James M} and Gautam Goel and Goldstein, {Kaela E} and Hand, {Holly L} and Neff, {Kristin M} and Alina Popp and Juha Taavela and Markku Maki and Jorma Isola and Williams, {Leslie J} and Truitt, {Kenneth E} and Anderson, {Robert P} and {RESET CeD Study Group}",

year = "2023",

doi = "10.1016/S2468-1253(22)00428-9",

language = "English",

volume = "8",

pages = "446--457",

number = "5",

}

Tye-Din, JA, Daveson, AJM, Goel, G, Goldstein, KE, Hand, HL, Neff, KM, Popp, A , Taavela, J , Maki, M , Isola, J, Williams, LJ, Truitt, KE, Anderson, RP & RESET CeD Study Group 2023, 'Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study', The Lancet gastroenterology & hepatology, Vuosikerta 8, Nro 5, Sivut 446-457. https://doi.org/10.1016/S2468-1253(22)00428-9

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study. / Tye-Din, Jason A; Daveson, A James M; Goel, Gautam et al.
julkaisussa: The Lancet gastroenterology & hepatology, Vuosikerta 8, Nro 5, 2023, s. 446-457.

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD)

T2 - an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

AU - Tye-Din, Jason A

AU - Daveson, A James M

AU - Goel, Gautam

AU - Goldstein, Kaela E

AU - Hand, Holly L

AU - Neff, Kristin M

AU - Popp, Alina

AU - Taavela, Juha

AU - Maki, Markku

AU - Isola, Jorma

AU - Williams, Leslie J

AU - Truitt, Kenneth E

AU - Anderson, Robert P

AU - RESET CeD Study Group

PY - 2023

Y1 - 2023

U2 - 10.1016/S2468-1253(22)00428-9

DO - 10.1016/S2468-1253(22)00428-9

M3 - Article

C2 - 36898393

SN - 2468-1253

VL - 8

SP - 446

EP - 457

JO - The Lancet gastroenterology & hepatology

JF - The Lancet gastroenterology & hepatology

IS - 5

ER -

Tye-Din JA, Daveson AJM, Goel G, Goldstein KE, Hand HL, Neff KM et al. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study. The Lancet gastroenterology & hepatology. 2023;8(5):446-457. doi: 10.1016/S2468-1253(22)00428-9